Compare · GLTO vs IVA
GLTO vs IVA
Side-by-side comparison of Galecto Inc. (GLTO) and Inventiva S.A. (IVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GLTO and IVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- IVA is the larger of the two at $1.09B, about 19.0x GLTO ($57.3M).
- Over the past year, GLTO is up 669.7% and IVA is up 42.0% - GLTO leads by 627.6 points.
- IVA has hit the wire 5 times in the past 4 weeks while GLTO has been quiet.
- IVA has more recent analyst coverage (17 ratings vs 4 for GLTO).
- Company
- Galecto Inc.
- Inventiva S.A.
- Price
- $28.17-2.07%
- $4.63+2.21%
- Market cap
- $57.3M
- $1.09B
- 1M return
- +27.35%
- +28.97%
- 1Y return
- +669.67%
- +42.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 0
- 5
- Recent ratings
- 4
- 17
Galecto Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Latest GLTO
- Galecto Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
- Amendment: SEC Form SCHEDULE 13G/A filed by Galecto Inc.
- Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
- SEC Form SCHEDULE 13G filed by Galecto Inc.
- UBS initiated coverage on Galecto with a new price target
- Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
- Director Bruno Julianne converted options into 129,000 shares, increasing direct ownership by 1,606% to 137,032 units (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 8,713,000 shares (SEC Form 4)
Latest IVA
- Cantor Fitzgerald initiated coverage on Inventiva
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
- SEC Form 6-K filed by Inventiva S.A.
- Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026
- Claret Capital Partners participates in €130m financing for Inventiva
- Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
- SEC Form 6-K filed by Inventiva S.A.